会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
    • MYO-2肽多聚体和肌醇六磷酸融合蛋白的表面表达载体及其转化的微生物
    • KR100857861B1
    • 2008-09-11
    • KR1020070103512
    • 2007-10-15
    • 주식회사 바이오리더스한국생명공학연구원충남대학교산학협력단
    • 성문희김철중부하령김지연김영숙허룡춘
    • C07K16/00C07K19/00
    • C07K14/475
    • A surface expression vector for fusion protein of Myo-2 peptide multimer and myostatin is provided to express the myostatin fusion protein on the surface of bacteria, and increase the blood antibody production, body weight and muscle amount of animals by orally administering the bacteria. A myostatin derived peptide Myo-2 has the amino acid sequence of SEQ ID NO:1. A Myo-2 peptide multimer is prepared by polymerizing 2-8 Myo-2 peptides. A fusion protein is prepared by fusing the Myo-2 peptide multimer with matured myostatin. A surface expression vector for fusion protein contains a gene encoding polygammaglutamic acid synthetase complex selected from pgsB(polygammaglutamic acid synthetase), pgsC and pgsA, the nucleotide sequence encoding the Myo-2 peptide multimer and a gene encoding the matured myostatin. A method for producing a fusion protein-surface expressed microorganism comprises the steps of: (a) expressing the fusion protein of myostatin derived peptide multimer and matured myostatin on the surface of microorganism by culturing a microorganism transformed with the surface expression vector; and (b) recovering the microorganism with surface expressed matured myostatin, wherein the microorganism is lactic acid bacterium. Further, the matured myostatin is be derived from mammal or birds.
    • 提供Myo-2肽多聚体和肌生成抑制素融合蛋白的表达表达载体,以表达细菌表面的肌生成抑制素融合蛋白,并通过口服施用细菌增加动物的血液抗体产生,体重和肌肉量。 肌生长抑制素衍生肽Myo-2具有SEQ ID NO:1的氨基酸序列。 通过聚合2-8个Myo-2肽制备Myo-2肽多聚体。 通过将Myo-2肽多聚体与成熟的肌生成抑制素融合来制备融合蛋白。 用于融合蛋白的表面表达载体包含编码聚腺苷酸合成酶复合物的基因,其选自pgsB(polygammaglutamic acid synthetase),pgsC和pgsA,编码Myo-2肽多聚体的核苷酸序列和编码成熟肌肉生长抑制素的基因。 一种融合蛋白表面表达微生物的制备方法,包括以下步骤:(a)通过培养用表面表达载体转化的微生物,将肌生长抑制素衍生肽多聚体和成熟肌生成抑制素的融合蛋白表达在微生物表面上; 和(b)用表面表达成熟的肌生长抑制素回收微生物,其中微生物是乳酸菌。 此外,成熟的肌生成抑制素来源于哺乳动物或鸟类。